Asupardo, Reahme M.
HRN: 21-37-93 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/02/2022
06/04/2022
IV
500mg
Q8h X 6 Doses
S/P LTCS
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominalReproductive Tract Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes